Free Trial
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:SCLX

Scilex Q1 2026 Earnings Report

Scilex logo
$7.04 +0.13 (+1.88%)
Closing price 04:00 PM Eastern
Extended Trading
$7.06 +0.02 (+0.28%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Scilex EPS Results

Actual EPS
-$4.76
Consensus EPS
-$0.34
Beat/Miss
Missed by -$4.42
One Year Ago EPS
N/A

Scilex Revenue Results

Actual Revenue
$8.61 million
Expected Revenue
$15.00 million
Beat/Miss
Missed by -$6.39 million
YoY Revenue Growth
N/A

Scilex Announcement Details

Quarter
Q1 2026
Date
5/20/2026
Time
Before Market Opens
Conference Call Date
Wednesday, May 20, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Scilex's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Scilex Earnings Headlines

Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...
June 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SCLX-Q/pressreleases/36701779/scilex-holding-company-scilex-announces-a-payment-date-of-june-15-2026-for-the-previously-announced-dividend-of-semnur-pharmaceuticals-inc-common-stock-to-holders-of-scilex-common-stock-and-other-eligible-equity-securities/
Scilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of ...
June 4, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-holding-company-scilex-announces-a-payment-date-of-june-15-2026-for-the-previously-announced-dividend-of-semnur-pharmaceuticals-inc-common-stock-to-holders-of-scilex-common-stock-and-1036225100
Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
June 9 at 1:00 AM  |  Brownstone Research (Ad)
Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306806/0/en/scilex-holding-company-scilex-announces-a-payment-date-of-june-15-2026-for-the-previously-announced-dividend-of-semnur-pharmaceuticals-inc-common-stock-to-holders-of-scilex-common-.html
Scilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other ...
May 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-holding-company-scilex-announces-its-board-of-directors-approved-a-dividend-of-semnur-pharmaceuticals-inc-common-stock-to-holders-of-scilex-common-stock-and-other-eligible-equity-1036188956
Scilex Holding Company Declares Dividend of Semnur Pharmaceuticals Common Stock to Shareholders
May 22, 2026  |  quiverquant.comQ
See More Scilex Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scilex? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scilex and other key companies, straight to your email.

About Scilex

Scilex (NASDAQ:SCLX) Holdings, Inc. (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways. The company’s pipeline includes additional topical and localized therapies designed to address a range of acute and chronic pain indications without the abuse potential associated with opioid medications. Scilex pursues both in-house research and selective licensing partnerships to broaden its offering.

Headquartered in San Diego, California, Scilex operates primarily in the U.S. market, where it works with healthcare providers, specialty pharmacies and distributors to ensure patient access to its products. The company’s management team brings experience in pharmaceutical development, regulatory affairs and commercial operations, supporting Scilex’s strategy of targeted growth within the pain therapeutics space.

View Scilex Profile
Earnings Tools